Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TAO Synergies Inc. (TAOX)

TAO Synergies: Two directors resign; Robert Ephron joins board; Jacks advisor deal

Neutral Impact 2 of 5 leadership Written later

TAO Synergies announced that directors Jonathan Schechter and Dr. Alan Tuchman resigned from the board on August 28, 2025, with Dr. Tuchman staying on as Chief Medical Officer, and that Robert Ephron was appointed to the board on August 29, 2025. The company also engaged Joseph Jacks as an advisor to its Bittensor-focused digital asset treasury strategy, issuing him warrants for 100,000 shares at $8.40 per share. The filing reports no financial results, and the resignations were described as voluntary and not tied to any disagreement with company operations.

Key points

  • Jonathan Schechter and Dr. Alan Tuchman resigned from the board and all committees on August 28, 2025; both resignations were described as voluntary.
  • Robert Ephron was appointed to the board on August 29, 2025, and will serve on the audit, compensation and nominating and corporate governance committees.
  • Joseph Jacks was engaged as an advisor; his one-year consulting agreement includes warrants for 100,000 shares at an exercise price of $8.40, expiring five years from issuance.

The filing

CompanyTAO Synergies Inc. (TAOX)
Form8-K, current report
Filed with the SECAug 29, 2025, 5:00 PM ET
Accession number0001104659-25-085770

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 29, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.